C. Englisch , S. Nopp , F. Moik , A.M. Starzer , P. Quehenberger , M. Preusser , A.S. Berghoff , C. Ay , I. Pabinger
{"title":"The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points","authors":"C. Englisch , S. Nopp , F. Moik , A.M. Starzer , P. Quehenberger , M. Preusser , A.S. Berghoff , C. Ay , I. Pabinger","doi":"10.1016/j.esmoop.2024.104130","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patients with cancer undergoing systemic therapies have a high risk for venous thromboembolism (VTE). Risk assessment models were developed to select high-risk subgroups that might benefit from primary thromboprophylaxis, yet currently available models reportedly underperform in contemporary cancer treatment populations and risk models across multiple time points throughout therapy are not available.</div></div><div><h3>Patients and methods</h3><div>We, therefore, aimed to validate the Vienna CATScore, a nomogram-based model including tumor type and continuous D-dimer levels, in a prospective cohort study of patients initiating contemporary systemic anticancer therapies. The validity of the model was tested at study inclusion, 3 weeks, and 3 months after start of therapy.</div></div><div><h3>Results</h3><div>Overall, 598 patients were included [49% women, median age 62 years (interquartile range 53-70 years)]. Most patients had stage IV disease (68.2%). The 6-month cumulative incidence of VTE was 9.2% [95% confidence interval (CI) 6.8% to 11.5%]. The Vienna CATScore demonstrated good discriminatory ability (c-statistics: 0.69, 95% CI 0.61-0.76) at study baseline and across all evaluated time points (c-statistics: 0.68, 95% CI 0.63-0.73). Applying a 6-month predicted VTE risk threshold of 8%, the CATScore effectively distinguished between low- and high-risk groups at study inclusion (7.1% versus 15.1% observed VTE risk, <em>P</em> = 0.004) and across all three time points (6.3% versus 13.6% observed VTE risk, <em>P</em> < 0.001). Assuming a 50% risk reduction with thromboprophylaxis, this threshold resulted in a number needed to treat (NNT) of 13 and 15, respectively, in the high-risk group, while the NNT was 28 and 32, respectively, in the low-risk group.</div></div><div><h3>Conclusions</h3><div>This external validation of the Vienna CATScore confirms its effectiveness in predicting VTE risk in the initial months of state-of-the-art systemic anticancer therapies and across multiple time points.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 2","pages":"Article 104130"},"PeriodicalIF":8.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S205970292401901X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Patients with cancer undergoing systemic therapies have a high risk for venous thromboembolism (VTE). Risk assessment models were developed to select high-risk subgroups that might benefit from primary thromboprophylaxis, yet currently available models reportedly underperform in contemporary cancer treatment populations and risk models across multiple time points throughout therapy are not available.
Patients and methods
We, therefore, aimed to validate the Vienna CATScore, a nomogram-based model including tumor type and continuous D-dimer levels, in a prospective cohort study of patients initiating contemporary systemic anticancer therapies. The validity of the model was tested at study inclusion, 3 weeks, and 3 months after start of therapy.
Results
Overall, 598 patients were included [49% women, median age 62 years (interquartile range 53-70 years)]. Most patients had stage IV disease (68.2%). The 6-month cumulative incidence of VTE was 9.2% [95% confidence interval (CI) 6.8% to 11.5%]. The Vienna CATScore demonstrated good discriminatory ability (c-statistics: 0.69, 95% CI 0.61-0.76) at study baseline and across all evaluated time points (c-statistics: 0.68, 95% CI 0.63-0.73). Applying a 6-month predicted VTE risk threshold of 8%, the CATScore effectively distinguished between low- and high-risk groups at study inclusion (7.1% versus 15.1% observed VTE risk, P = 0.004) and across all three time points (6.3% versus 13.6% observed VTE risk, P < 0.001). Assuming a 50% risk reduction with thromboprophylaxis, this threshold resulted in a number needed to treat (NNT) of 13 and 15, respectively, in the high-risk group, while the NNT was 28 and 32, respectively, in the low-risk group.
Conclusions
This external validation of the Vienna CATScore confirms its effectiveness in predicting VTE risk in the initial months of state-of-the-art systemic anticancer therapies and across multiple time points.
背景:接受全身治疗的癌症患者发生静脉血栓栓塞(VTE)的风险很高。风险评估模型是为了选择可能受益于初级血栓预防的高风险亚组而开发的,但据报道,目前可用的模型在当代癌症治疗人群中表现不佳,并且在整个治疗过程中多个时间点的风险模型也不可用。患者和方法:因此,我们旨在验证维也纳CATScore,这是一个基于nomogram模型,包括肿瘤类型和连续d -二聚体水平,在一项前瞻性队列研究中,患者开始进行当代全身抗癌治疗。模型的有效性在研究纳入、治疗开始后3周和3个月进行检验。结果:总共纳入598例患者[49%为女性,中位年龄62岁(四分位数范围53-70岁)]。大多数患者为IV期(68.2%)。6个月静脉血栓栓塞的累计发生率为9.2%[95%可信区间(CI) 6.8%至11.5%]。维也纳CATScore在研究基线和所有评估时间点显示出良好的区分能力(c-statistics: 0.69, 95% CI 0.61-0.76) (c-statistics: 0.68, 95% CI 0.63-0.73)。应用6个月预测VTE风险阈值为8%,CATScore在研究纳入时有效区分了低危组和高危组(7.1% vs 15.1%观察到的VTE风险,P = 0.004)和所有三个时间点(6.3% vs 13.6%观察到的VTE风险,P < 0.001)。假设使用血栓预防可以降低50%的风险,这个阈值导致需要治疗的数字(NNT)在高风险组分别为13和15,而在低风险组分别为28和32。结论:维也纳CATScore的外部验证证实了其在最先进的全身抗癌治疗的最初几个月和多个时间点预测静脉血栓栓塞风险方面的有效性。
期刊介绍:
ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research.
ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO.
Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.